Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

What this study is about

This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

Who can join (things the study team will check)

✅ You may be able to join if…

• Age ≥ 18
• Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days
• confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin.
• Ability to provided informed consent or through their substitute decision maker

🚫 You may not be able to join if…

• Type 1 DM
• Use of a GLP-1-RA within 30 days prior to screening
• Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)
• Confirmed pregnancy, women of childbearing potential
• Known hypersensitivity to GLP-1-RA
• Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months
• Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA

Where this trial is running

• Unity Health Toronto, Toronto, Ontario, Canada
• Unity Health Toronto, Toronto, Ontario, Canada

Who to contact

Ron Wald, MD · (416) 867-3703 · ron.wald@unityhealth.to

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07017270.